Axa
RCKT icon

Axa’s Rocket Pharmaceuticals RCKT Stock Holding History

Axa’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-170,863
Closed -$9.37M – 1311
2020
Q4 		$9.37M Sell
170,863
-41,323
-19% -$1.51M 0.03% 541
2020
Q3 		$4.85M Sell
212,186
-2,238
-1% -$55.1K 0.02% 632
2020
Q2 		$4.49M Buy
214,424
+10,993
+5% +$198K 0.02% 649
2020
Q1 		$2.84M Sell
203,431
-15,188
-7% -$301K 0.01% 663
2019
Q4 		$4.98M Buy
218,619
+4,636
+2% +$77.4K 0.02% 621
2019
Q3 		$2.49M Sell
213,983
-379
-0.2% -$4.7K 0.01% 815
2019
Q2 		$3.21M Buy
214,362
+4,678
+2% +$81.6K 0.01% 767
2019
Q1 		$3.68M Buy
209,684
+47,856
+30% +$756K 0.01% 721
2018
Q4 		$2.4M Buy
161,828
+33,206
+26% +$551K 0.01% 783
2018
Q3 		$3.17M Buy
+128,622
New +$2.79M 0.01% 786

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Axa's RCKT Position: Q1 2021 in Review

Axa sold out of Rocket Pharmaceuticals (RCKT) in Q1 2021, closing a stake of 170,863 shares — an estimated $9.37M sold.

Axa first reported a position in RCKT in Q3 2018 and held it in 10 quarters. The position peaked at $9.37M in Q4 2020. 173 funds tracked by Wall St. Rank hold RCKT as of Q1 2021.

  • Axa reported no remaining Rocket Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Axa sold 170,863 Rocket Pharmaceuticals shares in Q1 2021, an estimated $9.37M.
  • Axa first reported a position in Rocket Pharmaceuticals in Q3 2018 and held it in 10 quarters.
  • Axa's Rocket Pharmaceuticals position peaked at $9.37M in Q4 2020.
  • 173 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2021.

Based on Axa's 13F filing for Q1 2021, filed 14 May 2021.